You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
Dow
Johnson and Johnson
Merck

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 8,623,395

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,623,395
Title:Implantable therapeutic device
Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
Inventor(s): de Juan, Jr.; Eugene (Menlo Park, CA), Alster; Yair (Menlo Park, CA), Farinas; Kathleen Cogan (Menlo Park, CA), MacFarlane; K. Angela (Menlo Park, CA), Reich; Cary J. (Menlo Park, CA), Campbell; Randolph E. (Menlo Park, CA)
Assignee: ForSight Vision4, Inc. (Menlo Park, CA)
Application Number:13/204,638
Patent Claims:see list of patent claims

Details for Patent 8,623,395

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial ForSight Vision4, Inc. (Menlo Park, CA) 2030-08-05 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial ForSight Vision4, Inc. (Menlo Park, CA) 2030-08-05 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial ForSight Vision4, Inc. (Menlo Park, CA) 2030-08-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Moodys
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.